Our team is studying the relevance of the transcription factor NRF2 (Nuclear factor (erythroid-derived 2)-like 2), a master regulator of oxidant and inflammatory defense, as a new therapeutic target in PD. This evidence concerns the gene NFE2L2 and Parkinson disease.